A3480

Atosiban

≥98% (HPLC), oxytocin receptor antagonist, lyophilized powder

• Synonim(y): 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin, 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin, Tractocile
• Wzór empiryczny (zapis Hilla): C₄₃H₆₇N₁₁O₁₂S₂
• Numer CAS: 90779-69-4
• Masa cząsteczkowa: 994.19
• UNSPSC Code: 51111800
• PubChem Substance ID: 24724390
• NACRES: NA.77
• MDL number: MFCD00672436
• Assay: ≥98% (HPLC)
• Form: lyophilized powder
• Quality level: 100
• Storage condition: desiccated

Właściwości

• Nazwa produktu: Atosiban, ≥98% (HPLC)
• Quality Level: 100
• assay: ≥98% (HPLC)
• form: lyophilized powder
• storage condition: desiccated
• color: white
• solubility: H₂O: ≤100 mg/mL
• originator: Ferring
• shipped in: wet ice
• storage temp.: −20°C
• SMILES string: [H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](Cc2ccc(OCC)cc2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O
• InChI: 1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
• InChI key: VWXRQYYUEIYXCZ-OBIMUBPZSA-N
• Gene Information: human ... AVPR1A(552), OXTR(5021) ; rat ... Oxtr(25342)

Opis

Application

Atosiban has been used:

• as an oxytocin receptor antagonist
• in the calcium mobilization assay for Z factor determination in uterine myometrium (UT-myo cells) and as a therapeutic agent to inhibit preterm labor
• to inhibit the activation of oxytocin-receptor-expressing neurons in the parabrachial nucleus of mice (Oxtr^PBN)

Biochem/physiol Actions

Atosiban is a peptide oxytocin receptor antagonist.

Atosiban efficiently prevent preterm uterine contractions without any major cardiovascular, pulmonary or central nervous system side effects. It has potential to treat preterm labour.

Features and Benefits

This compound was developed by Ferring. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Reconstitute in deionized water at not less than 100 μg/mL, which can then be diluted into aqueous vehicle of choice. Solutions may be stored at 2-8 °C for up to seven days. For extended storage, add a carrier protein of 0.1% human serum albumin or bovine serum albumin and freeze in working aliquots at −20 °C.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable